Navigation Links
Potential new drug for some patients with treatment-resistant lung cancer
Date:10/20/2013

BOSTON The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung cancer, non-small cell lung cancer (NSCLC). Most NSCLCs harboring these EGFR mutations, called activating mutations, respond to the EGFR inhibitor drugs erlotinib and gefitinib. A majority of such cancers, however, develop resistance to these drugs within about nine to 11 months. In many cases, this is due to the cancer cells acquiring a second mutation called EGFR T790M, also known as the "resistance mutation."

"There are no approved therapies to treat lung cancer patients who develop the second mutation in the EGFR that stops the currently available medicines from working," said Susan Galbraith, M.D., Ph.D., head of the Oncology Innovative Medicines Unit at AstraZeneca. "The innovative breakthrough was finding a series of molecules that could target both the activating and resistance mutant forms of EGFR more potently than normal EGFR, which led to development of the new EGFR kinase inhibitor, AZD9291.

"AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines," she added.

The AstraZeneca scientists first showed that AZD9291 potently inhibited lung cancer cells with mutant EGFR, grown in lab dishes. They then tested the drug on mice bearing lung tumors with activating mutations and mice bea
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study identifies potential treatment for lethal childhood leukemia
2. McMaster researchers find potential for new uses of old drug
3. Army researcher develops potential vaccine carrier
4. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
5. New study of NIH funding allocations suggests potential efficiency gains
6. A closer look at PARP-1 reveals potential new drug targets
7. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
8. VCU Massey Cancer Center sees potential in novel leukemia treatment
9. Misuse of over-the-counter pain medication is potential health threat
10. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
11. Bioinformatics experts at the CNIO explore additional coding potential hidden in the human genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The Alaska Center for Dentistry at ... Jonathan Oudin, DDS, who will begin working July 21. ... for three years. According to Teresa Wallace, Office Manager, ... help take on new patients. , "This will allow ... serving the greater Anchorage metro community," Wallace said. "Dr. ...
(Date:7/31/2014)... 31, 2014 (HealthDay News) -- Transplant surgeons often ... flags for burnout, a new study suggests. ... study reported having a low sense of personal ... feeling emotionally exhausted, researchers found. "Burnout is ... transplantation," study co-author Dr. Marwan Abouljoud, director of ...
(Date:7/31/2014)... algorithm aimed to diagnose pediatric patients with suspected ... scans, without affecting diagnostic accuracy, Mayo Clinic Children,s ... published in the journal Surgery . , ... acute abdominal pain in children. Appendicitis occurs when ... CT scans are often used to diagnose acute ...
(Date:7/31/2014)... recent fears of invasive lionfish causing fish poisoning may ... by fishing derbies and targeted fisheries may remain the ... simple way to know for sure whether a lionfish ... , Pacific lionfish were first reported off the coast ... swiftly in number ever since. They,re now found in ...
(Date:7/31/2014)... July 31, 2014 Setting goals for a ... blogs on successful tips to weight loss. Fitness on the ... over 8 years, and has worked with 6000 customers on ... have had the chance to monitor why customers start exercising ... how long they stick to their program, whether or not ...
Breaking Medicine News(10 mins):Health News:Dr. Jonathan Oudin to Join Alaska Center for Dentistry at Wasilla Location 2Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2Health News:Invasive lionfish likely safe to eat after all 2Health News:Invasive lionfish likely safe to eat after all 3Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2
... web for robots this is the aim of a ... Universitaet Muenchen (TUM). This worldwide database will enable robots in ... thus speeding up the process of adopting new operations. The ... and has a budget of 5.6 million euros. One ...
... of Southampton and Synairgen Research Ltd, a respiratory drug ... a Phase II study into the effectiveness of the ... increase in the frequency of asthma attacks (also known ... viruses because the lungs of patients with the condition ...
... ... subliminal and binaural visualization techniques, today announced that his iPhone and iPod touch app ... ... neuropsychologist and expert in subliminal and binaural visualization techniques, today announced that his iPhone ...
... ... Trade World, Inc. group of products. This new agreement covers all of the West ... ... VisionQwest Resource Group, Inc. www.vqrginc.com ) has signed a formal marketing and distribution agreement ...
... ... of Austin Texas announces general availability of the Test Coverage Tool for C# ... new code can be compiled and run to determine exactly what lines of ... graphic display of code coverage along with overall metrics is the result of ...
... ... Behind Their Products , ... UT (Vocus) April 8, 2010 -- Tahitian Noni International (TNI) now has 14 ... on the way. TNI has more human clinical studies than any network marketing superfruit company ...
Cached Medicine News:Health News:European collaboration seeks to create 'World Wide Web' for robots 2Health News:Southampton scientists begin Phase II patient trial for new asthma treatment 2Health News:Sales are on the Rise for Professor McMurphy's Subliminal and Binaural Visualization iPhone Apps 2Health News:Sales are on the Rise for Professor McMurphy's Subliminal and Binaural Visualization iPhone Apps 3Health News:VisionQwest Global Group Signs Distribution Agreement with Creative Trade World, Inc. 2Health News:VisionQwest Global Group Signs Distribution Agreement with Creative Trade World, Inc. 3Health News:Know What Works with Semantic Design's Test Coverage Analysis Tool for C#/.Net 2Health News:Know What Works with Semantic Design's Test Coverage Analysis Tool for C#/.Net 3Health News:14 Human Clinical Studies Prove the Efficacy of Tahitian Noni Bioactive Beverages 2
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014  ResMed Inc. (NYSE: ... and for the fiscal year ended June 30, 2014.  Revenue ... quarter ended June 30, 2013 (a 1 percent decrease on ... increase of 20 percent compared to the quarter ended June ... $0.61, an increase of 22 percent compared to the quarter ...
(Date:7/31/2014)... -- Xencor Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... for the second quarter ended June 30, 2014 and ... "In the second quarter, we presented preclinical ... Conference (ATS) demonstrating three novel mechanisms of action ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6
Blunt, 20 cm long....
Autoclavable reusable pencil for Aaron 800 & 1200 - comes with generator or 1/box....
400 Series Monopolar Foot Activated Forceps...
Extended angled sharp electrode - 1/box....
Medicine Products: